December 2023

– NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells – SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ — Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: